Research

Overview of Peptide-Based Research Systems

Peptides represent a fundamental class of biologically active molecules involved in regulating cell signalling, metabolism, endocrine pathways, and neurophysiological processes. These molecules typically function via highly specific receptor interactions, most commonly through G protein-coupled receptors (GPCRs), enabling precise modulation of intracellular signalling cascades (Smith et al., 2021).

Advances in peptide engineering have resulted in synthetic analogues with significantly improved pharmacological properties, including enhanced metabolic stability, receptor selectivity, and prolonged systemic half-life (Fosgerau & Hoffmann, 2015).

Metabolic Peptides & Incretin Pathways

Incretin hormones, particularly glucagon-like peptide-1 (GLP-1), are among the most intensively studied peptide systems in metabolic research. GLP-1 regulates:

  • insulin secretion in a glucose-dependent manner
  • glucagon suppression
  • gastric emptying
  • appetite and energy intake

These effects are mediated through activation of intracellular pathways such as cAMP-dependent signalling and protein kinase cascades (Drucker, 2018).

Multi-Receptor Agonism

Recent developments focus on multi-target peptide analogues:

  • Semaglutide → GLP-1 receptor agonist
  • Tirzepatide → dual GLP-1/GIP agonist
  • Retatrutide → GLP-1/GIP/glucagon triple agonist

Triple receptor agonism combines insulinotropic, anorexigenic, and energy expenditure–enhancing pathways, resulting in amplified metabolic effects compared to single receptor activation (Coskun et al., 2022; Jastreboff et al., 2023).

Growth Hormone Secretagogues & Endocrine Regulation

Growth hormone releasing peptides (GHRPs) interact with the growth hormone secretagogue receptor (GHS-R1a), which is also activated by ghrelin. Activation of this receptor leads to:

  • stimulation of pulsatile growth hormone release
  • modulation of hypothalamic–pituitary axis signalling
  • downstream effects on metabolism and anabolic processes

Studies demonstrate that combining GHRPs with GHRH analogues results in a synergistic increase in growth hormone secretion (Bowers et al., 1993; Ghigo et al., 2005).

Structural analyses further suggest that peptide conformation and membrane interaction dynamics play a key role in receptor binding efficiency and downstream signalling (Casati et al., 2000).

Regenerative Peptides & Tissue Remodelling

The copper-binding tripeptide GHK-Cu has been extensively studied for its regenerative and reparative properties. Research demonstrates that GHK-Cu can:

  • stimulate collagen synthesis (types I and III)
  • promote angiogenesis via VEGF signalling
  • regulate inflammatory mediators
  • influence extracellular matrix remodelling

These mechanisms are driven by its ability to modulate gene expression and activate repair pathways at the cellular level (Pickart & Margolina, 2018; Maquart et al., 1988).

Neuropeptides & CNS Signalling

Neuropeptides such as oxytocin play a central role in neuroendocrine and behavioural regulation. Oxytocin is a cyclic nonapeptide that binds to the OXTR receptor, activating intracellular signalling through:

  • phospholipase C (PLC)
  • inositol triphosphate (IP₃)
  • calcium mobilization

These pathways influence neuronal activity, stress responses, and social behaviour (Lee et al., 2009).

Oxytocin receptors are widely expressed in both central and peripheral tissues, contributing to effects in the central nervous system, cardiovascular regulation, and metabolic processes (Gimpl & Fahrenholz, 2001).

Molecular Optimization & Peptide Engineering

Modern peptide therapeutics and research compounds frequently include structural modifications designed to enhance functionality:

  • lipidation (fatty acid conjugation) → prolongs circulation time via albumin binding
  • amino acid substitutions → increase resistance to enzymatic degradation
  • PEGylation or linkers → improve pharmacokinetic stability
  • lyophilization → ensures long-term stability and reproducibility

These innovations have enabled peptides to transition from short-lived signalling molecules into long-acting, highly specific research tools (Lau & Dunn, 2018).

Limitations & Research Considerations

Despite extensive advances, several limitations remain:

  • incomplete characterization of complex signalling networks
  • variability between in vitro, animal, and human models
  • receptor-specific response variability and signalling bias

Ongoing research focuses on systems pharmacology, receptor selectivity, and long-term biological impact, aiming to improve translational relevance (Insel et al., 2019).

References 

*Tie jednotlive linky su dostupne pre verejnost spolu s blizsou informaciou

Bowers, C. Y., Momany, F. A., Reynolds, G. A., & Hong, A. (1993).
On the in vitro and in vivo activity of growth hormone-releasing peptides.
Endocrinology, 132(1), 243–248.
https://doi.org/10.1210/endo.132.1.8419130

Casati, C., et al. (2000).
Structure–activity relationships of growth hormone-releasing peptides.
Journal of Endocrinological Investigation, 23(3), 140–148.

Coskun, T., et al. (2022).
LY3437943, a novel triple incretin receptor agonist (GLP-1, GIP, glucagon), for the treatment of metabolic disorders.
Cell Metabolism, 34(3), 409–424.
https://doi.org/10.1016/j.cmet.2022.01.015

Drucker, D. J. (2018).
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.
Cell Metabolism, 27(4), 740–756.
https://doi.org/10.1016/j.cmet.2018.03.001

Fosgerau, K., & Hoffmann, T. (2015).
Peptide therapeutics: current status and future directions.
Drug Discovery Today, 20(1), 122–128.
https://doi.org/10.1016/j.drudis.2014.10.003

Ghigo, E., Arvat, E., Muccioli, G., & Camanni, F. (2005).
Growth hormone-releasing peptides.
Endocrine Reviews, 26(3), 424–448.
https://doi.org/10.1210/er.2004-0002

Gimpl, G., & Fahrenholz, F. (2001).
The oxytocin receptor system: structure, function, and regulation.
Physiological Reviews, 81(2), 629–683.
https://doi.org/10.1152/physrev.2001.81.2.629

Insel, P. A., et al. (2019).
GPCRomics: GPCR Expression in Health and Disease.
Trends in Pharmacological Sciences, 40(11), 907–920.
https://doi.org/10.1016/j.tips.2019.09.005

Jastreboff, A. M., et al. (2023).
Triple–hormone-receptor agonist retatrutide for obesity.
New England Journal of Medicine, 389(6), 514–526.
https://doi.org/10.1056/NEJMoa2301972

Lau, J. L., & Dunn, M. K. (2018).
Therapeutic peptides: Historical perspectives, current development trends, and future directions.
Bioorganic & Medicinal Chemistry, 26(10), 2700–2707.
https://doi.org/10.1016/j.bmc.2017.06.052

Lee, H. J., Macbeth, A. H., Pagani, J. H., & Young, W. S. (2009).
Oxytocin: the great facilitator of life.
Progress in Neurobiology, 88(2), 127–151.
https://doi.org/10.1016/j.pneurobio.2009.04.001

Maquart, F. X., et al. (1988).
Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex Gly-His-Lys-Cu2+.
FEBS Letters, 238(2), 343–346.
https://doi.org/10.1016/0014-5793(88)80058-7

Pickart, L., & Margolina, A. (2018).
Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data.
International Journal of Molecular Sciences, 19(7), 1987.
https://doi.org/10.3390/ijms19071987

Smith, J. S., Lefkowitz, R. J., & Rajagopal, S. (2021).
Biased signalling: from simple switches to allosteric microprocessors.
Nature Reviews Drug Discovery, 20(3), 185–206.
https://doi.org/10.1038/s41573-020-0094-0